Biotechnology 6 May 2026 - 24 May 2026

Aura Biosciences Stock Falls After Eye-Cancer Trial News
····

Aura Biosciences Stock Falls After Eye-Cancer Trial News

Aura Biosciences shares dropped roughly 4.2% to $6.89 late Tuesday, lagging a soft biotech sector. This came after Aura said on Monday that it hit a clinical-trial milestone. The SPDR S&P Biotech ETF slid about 4.2%. The iShares Nasdaq Biotechnology ETF lost around 2.9%. Aura said Monday it finished enrolling 108 patients in CoMpass, its Phase 3 study of bel-sar for early choroidal melanoma. Phase 3 trials are key late-stage tests before a drug approval. The first main results, or “topline” data, are due in the second half of 2027.
June 2, 2026
Ocugen Shares Flat Ahead of Holiday-Shortened Week for Eye-Therapy Bid
····

Ocugen Shares Flat Ahead of Holiday-Shortened Week for Eye-Therapy Bid

Ocugen Inc. goes into the Monday market holiday stuck around $1.34. Trading was muted for the biotech stock on Friday ahead of the Memorial Day break, with shares showing little movement. Nasdaq traders are off Monday, May 25, for Memorial Day. That means Tuesday is when investors can trade Ocugen shares after last week's moves and look ahead to the company's upcoming ophthalmology events.
May 24, 2026
NovoCure Stock Still Up Ahead of Cancer Trial Data
····

NovoCure Stock Still Up Ahead of Cancer Trial Data

NovoCure shares climbed 0.3% Friday, closing the week at $17.96, up 2.2% from last Friday. After the bell, the stock fell to $17.71, with moves more volatile as volume dropped. Small move, but the timing stands out. NovoCure shares are holding around 50% higher than where they closed on April 29, right before the cancer device maker posted Q1 numbers and hiked its 2026 revenue forecast.
May 24, 2026
Cardiff Oncology Sets June ASCO Data Reveal as CRDF Stock Test Nears
····

Cardiff Oncology Sets June ASCO Data Reveal as CRDF Stock Test Nears

Cardiff Oncology was flat on Friday. The biotech said it plans an investor webcast in June to go over new mid-stage data for onvansertib, the company’s main candidate in first-line RAS-mutated metastatic colorectal cancer. Cardiff’s key moment comes with its ASCO presentation on June 2 and the webcast the following morning, which will be the next look at the CRDF-004 trial. That trial is now front and center for the company. Shares ended at $1.78, off 0.6%. After hours, the stock was hovering around $1.79.
May 23, 2026
Kodiak Sciences Falls Before Holiday Pause With Eyes on Drug Update
····

Kodiak Sciences Falls Before Holiday Pause With Eyes on Drug Update

Kodiak Sciences Inc. ended Friday down 3.2% at $36.23, giving up some of the previous day’s jump before the U.S. market’s three-day weekend. The retina-drug maker changed hands between $36.01 and $37.75, with 500,620 shares traded, according to LSEG figures posted on the company’s investor site. Kodiak’s stock is now trading off the outlook for Zenkuda, its experimental eye drug, more than financial numbers. The company’s investor site hadn’t posted any update beyond the May 7 quarterly release as of late Friday.
May 22, 2026
Xenetic Biosciences Shares Edge Down Ahead of ASCO Update
····

Xenetic Biosciences Shares Edge Down Ahead of ASCO Update

Xenetic Biosciences slipped 4 cents to $2.90 early Friday, with just 144 shares changing hands. Investors mostly ignored the latest quarterly numbers, focusing instead on the company’s upcoming ASCO event. Market cap stood near $6.6 million as the session got started. Low volume can swing micro-cap biotech stocks like this. Just a few trades move the price, and the market sits tight for specific events: new data, clinical trial news, a financing, or word on a strategic review. Since Xenetic’s May 13 first-quarter update, the company's site hasn’t posted anything new. The filings page still shows a May 14 Schedule 13G/A, a May 13 8-K, and a May 12 10-Q as the latest updates.
May 22, 2026
DCOY Sets May 22 Vote, Puts Focus Back on Thinly Traded Stock
····

DCOY Sets May 22 Vote, Puts Focus Back on Thinly Traded Stock

Decoy Therapeutics Inc. was active ahead of Friday’s open with the company hitting the record date for its 2026 annual meeting. The governance step comes with DCOY shares coming off a choppy week. Decoy, based in Houston, said shareholders on record as of May 22 can vote at its annual meeting on July 14. The record date sets which shareholders can vote. Decoy said in a filing that proposals and director nominations must be in by the close of business May 29.
May 22, 2026
Ultragenyx (RARE) Moves Before Friday’s Bell
····

Ultragenyx (RARE) Moves Before Friday’s Bell

Ultragenyx Pharmaceutical Inc. was up in premarket trade Friday after Cantor Fitzgerald raised its price target on the company and flagged its late-stage Angelman syndrome program. Shares finished Thursday at $23.71, gaining 1.45%, and were at $24.06 at 7:50 a.m. Eastern in the extended session. Cantor lifted its price target on Ultragenyx to $96 from $84 and stayed at Overweight, the bank’s way of saying it sees the stock topping the peer group. The firm also raised its success odds for GTX-102, Ultragenyx’s Angelman syndrome therapy candidate, bumping the probability to 60% from 25%.
May 22, 2026
Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore
····

Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore

Tyra Biosciences shares were last quoted at $33.02 before Friday’s regular Nasdaq session, keeping the clinical-stage biotech below its 52-week high as investors weighed a fresh rare-cancer awareness push against a year still driven by trial data. The stock’s 52-week range was $8.75 to $40.65, with market value near $2 billion. Friday is not a U.S. stock-market holiday. Nasdaq’s calendar lists Memorial Day, Monday, May 25, as closed, leaving TYRA set for a normal regular session unless company-specific news or broader biotech flows shift the tape.
May 22, 2026
Cocrystal Pharma Moves Lower as Norovirus Program Draws Fresh Attention
····

Cocrystal Pharma Moves Lower as Norovirus Program Draws Fresh Attention

Cocrystal Pharma fell to $1.11 in thin volume Thursday as the market looked for new updates from the company’s norovirus drug work. Shares changed hands between $1.09 and $1.11. The SPDR S&P Biotech ETF was also a touch lower. COCP’s move is notable. The stock trades as a micro-cap, with its market value at about $15.3 million as of the latest quote. Fewer than 20,000 shares traded, so small orders can swing the price sharply and old news can hit harder.
May 21, 2026
Bio-Techne Shares Bounce, Investors Eye a Key Risk
····

Bio-Techne Shares Bounce, Investors Eye a Key Risk

Bio-Techne Corp is coming into Thursday’s U.S. session with shares up for three days. The stock finished Wednesday at $46.70, gaining 2.7%. As of the dateline, the regular Nasdaq session was still ahead. Nasdaq’s standard hours run 9:30 a.m. to 4:00 p.m. Eastern. Its next scheduled May 2026 closing is Memorial Day on May 25. BIO-TECHNE STAYS UNDER PRESSURE AS RALLY FIZZLES The rally is still a repair move right now. Bio-Techne is well under its January peak, with investors cutting the stock this month after fiscal Q3 sales came in below forecasts.
May 21, 2026
Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data
····

Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data

Vanda Pharmaceuticals VNDA dipped in early premarket trade Thursday, off 0.5% at $6.15 before the bell. Shares closed at $6.18 on Wednesday, when the stock climbed 3.2%. Investors looked at the drugmaker’s latest investor meetings and balanced that with concerns about costs for new product launches. Vanda is shifting focus from regulatory wins to showing product sales now. The Washington company recently launched Nereus for motion-induced vomiting and Bysanti for schizophrenia and acute bipolar I disorder, putting them in a lineup with Fanapt, Hetlioz and Ponvory.
May 21, 2026
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear
····

Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear

Neurogene Inc. shares barely moved in premarket trading on Nasdaq Thursday. Investors looked past new disclosures and kept their eyes on the upcoming clinical milestone for NGN-401, the lead gene therapy for Rett syndrome. The stock finished Wednesday at $26.95, gaining 7 cents, or 0.3%. It traded in a range from $26.50 to $28.08. Broader markets rallied too, with the Nasdaq Composite adding 1.5% and the Russell 2000 up 2.6% on Wednesday.
May 21, 2026
ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data
······

ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data

argenx SE’s U.S. shares inched up Wednesday, trailing the biotech sector after Immunovant released rheumatoid-arthritis data that drew new focus to the same drug class as argenx’s VYVGART franchise. ARGX was trading at $803.67 near the end of the session, up 0.7%. The iShares Nasdaq Biotechnology ETF added 2.1% and SPDR S&P Biotech ETF climbed 3.8%. Shares of Immunovant soared 35.1%. Roivant Sciences, Immunovant’s parent, rose 14.6%, according to market data.
May 20, 2026
NervGen Stock Climbs with Trial Approaching, Cash Burn Still a Focus
····

NervGen Stock Climbs with Trial Approaching, Cash Burn Still a Focus

NervGen Pharma Corp. was up almost 4% to $3.70 in midday Nasdaq trade Wednesday, lifted by its latest quarterly update as the company preps for its late-stage RESTORE trial. Shares moved between $3.58 and $3.75 and about 59,940 shares were traded. NervGen is moving from lining up with regulators to actually starting work. The company said this week it’s got an agreement with the U.S. Food and Drug Administration on RESTORE, the registrational study of NVG-291 for chronic tetraplegia, where all four limbs are paralyzed. CEO Adam Rogers said NervGen is “firmly in execution mode.” Site activation has started, and the study is still on track to kick off in mid-2026.
May 20, 2026
CSL Limited Share Price Slides Again as $5 Billion Writedown Puts Biotech Turnaround on the Clock
····

CSL Limited Share Price Slides Again as $5 Billion Writedown Puts Biotech Turnaround on the Clock

CSL Limited shares slipped again on Thursday, deepening the week’s losses for the Australian biotech after investors were rattled by a profit warning and upcoming writedowns. The stock wrapped up at A$97.26, off 1.55%, based on delayed quotes after the bell. CSL’s stock is still stuck around where it was in early 2017 — a level not seen in years. Monday’s 90-day strategic review, led by interim CEO Gordon Naylor, only deepened the slump. Reuters said shares slid as much as 17.8% that day, touching A$98.590, a low not reached since Jan. 19, 2017.
May 14, 2026
CSL Limited Share Price Plunge: Why a $5 Billion Writedown Hammered the ASX Biotech Giant
···

CSL Limited Share Price Plunge: Why a $5 Billion Writedown Hammered the ASX Biotech Giant

CSL Limited shares tumbled 16% on Monday, closing at A$100.75—after dipping under A$100 intraday, a level not seen in nearly ten years. The Australian blood-products and vaccine manufacturer slashed its forecast for fiscal 2026 and warned of around US$5 billion in fresh non-cash, pre-tax impairments. These writedowns hit asset values but don’t drain cash right away. This wasn’t just a regular earnings update. Interim Chief Executive Gordon Naylor delivered his 90-day review since stepping in back in February, spotlighting Vifor—the business CSL acquired for US$11.7 billion in 2022—right back in the thick of the company’s issues.
May 11, 2026
GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight
······

GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight

A U.S. federal judge has tossed Acuitas Therapeutics Inc.’s attempt to shield Pfizer and BioNTech’s Comirnaty Covid-19 vaccine from GSK’s patent claims, handing the British pharma giant a procedural victory in the ongoing mRNA legal fight. Judge Gregory B. Williams sided with GSK, dismissing the Acuitas case on grounds that the court lacked subject-matter jurisdiction—essentially, it didn’t have the authority to weigh in as presented, according to Bloomberg Law on Friday. The decision keeps the spotlight fixed on the main Delaware showdown involving GSK, Pfizer and BioNTech, instead of letting a supplier-driven lawsuit muddy the waters. Back in 2024, GSK filed suit against Pfizer and BioNTech, claiming Comirnaty stepped on patents for mRNA vaccine technology the company says it created
May 9, 2026
Bayer Bets $2.45 Billion on Perfuse Eye Drug as Eylea Pressure Builds
····

Bayer Bets $2.45 Billion on Perfuse Eye Drug as Eylea Pressure Builds

Bayer AG agreed to buy San Francisco-based Perfuse Therapeutics Inc. for as much as $2.45 billion, handing the German group a new eye-drug candidate as pressure builds on some of its older blockbusters. The deal includes $300 million upfront, with the rest tied to development, regulatory and commercial milestones. The timing matters. Eylea, Bayer’s top-selling pharmaceutical product, brought in €3.11 billion in 2025, down 5.9%, and Bayer said the drug was hit by lower prices and competition from generics.
May 6, 2026
1 2 3 4 5